Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Lancet Gastroenterol Hepatol
    May 2024
  1. BETHLEHEM L, Estevinho MM, Grinspan A, Magro F, et al
    Microbiota therapeutics for inflammatory bowel disease: the way forward.
    Lancet Gastroenterol Hepatol. 2024;9:476-486.
    >> Share

  2. FUMERY M, Buisson A
    Has the time come for a systematic top-down approach in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2024;9:394-395.
    >> Share

    April 2024
  3. PARKES GC, Hedin CRH
    PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00088.
    >> Share

  4. CHANCHLANI N, Lin S, Bewshea C, Hamilton B, et al
    Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
    Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00044.
    >> Share

    March 2024
  5. BALDERRAMO D, Quaresma AB, Olivera PA, Savio MC, et al
    Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America.
    Lancet Gastroenterol Hepatol. 2024;9:263-272.
    >> Share

  6. RIVIERE P, Li Wai Suen C, Chaparro M, De Cruz P, et al
    Acute severe ulcerative colitis management: unanswered questions and latest insights.
    Lancet Gastroenterol Hepatol. 2024;9:251-262.
    >> Share

    February 2024
  7. CHAPMAN TP, Ahmad T, Satsangi J
    Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?
    Lancet Gastroenterol Hepatol. 2024 Feb 22:S2468-1253(23)00406.
    >> Share

  8. NOOR NM, Lee JC, Bond S, Dowling F, et al
    A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034.
    >> Share

  9. CICCOCIOPPO R, Gaspar L
    Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere.
    Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(24)00004.
    >> Share

  10. LINDSAY JO, Hind D, Swaby L, Berntsson H, et al
    Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, ra
    Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(23)00460.
    >> Share

    January 2024
  11. SEBASTIAN S, Siegmund B, Teferra F, McGovern DPB, et al
    Promoting equity in inflammatory bowel disease: a global approach to care.
    Lancet Gastroenterol Hepatol. 2024 Jan 11:S2468-1253(23)00368.
    >> Share

    December 2023
  12. FUMERY M, Buisson A
    Guselkumab in Crohn's disease: the IL-23 race continues.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00356.
    >> Share

  13. DANESE S, Panaccione R, Feagan BG, Afzali A, et al
    Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00318.
    >> Share

    October 2023
  14. DIBLEY L, Duffy M
    Inflammatory bowel disease health care for LGTBQIA+ patients.
    Lancet Gastroenterol Hepatol. 2023 Oct 20:S2468-1253(23)00352.
    >> Share

  15. PATHIYIL MM, Jena A, Venkataramana Raju AK, Omprakash TA, et al
    Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2023 Oct 10:S2468-1253(23)00193.
    >> Share

  16. QUAN J, Markovinovic A, Hracs L, Ma C, et al
    Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Oct 6:S2468-1253(23)00310.
    >> Share

    September 2023
  17. VERMEIRE S, Danese S, Zhou W, Ilo D, et al
    Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-bl
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00208.
    >> Share

  18. ATREYA R, Neurath MF
    Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00271.
    >> Share

    August 2023
  19. SENIOR K
    Surgery in Crohn's disease: patients need MDT-led holistic care.
    Lancet Gastroenterol Hepatol. 2023 Aug 8:S2468-1253(23)00274.
    >> Share

  20. SHIN A
    Psychological therapies in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00229.
    >> Share

  21. RIGGOTT C, Mikocka-Walus A, Gracie DJ, Ford AC, et al
    Efficacy of psychological therapies in people with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00186.
    >> Share

    July 2023
  22. PARIGI TL, D'Amico F, Abreu MT, Dignass A, et al
    Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
    Lancet Gastroenterol Hepatol. 2023 Jul 6:S2468-1253(23)00154.
    >> Share

    May 2023
  23. JULSGAARD M, Mahadevan U, Vestergaard T, Mols R, et al
    Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 May 31:S2468-1253(23)00158.
    >> Share

  24. JAGT JZ, van Rheenen PF, Thoma SMA, Gower J, et al
    The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership.
    Lancet Gastroenterol Hepatol. 2023 May 22:S2468-1253(23)00140.
    >> Share

  25. JENA A, Sharma V, Sebastian S
    Reducing disparities in training in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 May 10:S2468-1253(23)00105.
    >> Share

  26. BRIERLEY R
    18th Congress of the European Crohn's and Colitis Organisation.
    Lancet Gastroenterol Hepatol. 2023;8:404.
    >> Share

  27. LOUIS E
    Treatment de-escalation in Crohn's disease - Author's reply.
    Lancet Gastroenterol Hepatol. 2023;8:401-402.
    >> Share

  28. MCSHANE C, Kevans D
    Treatment de-escalation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2023;8:401.
    >> Share

  29. THE LANCET GASTROENTEROLOGY HE
    The economic burden of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023;8:391.
    >> Share

    April 2023
  30. SINGH S, Boland BS, Jess T, Moore AA, et al
    Management of inflammatory bowel diseases in older adults.
    Lancet Gastroenterol Hepatol. 2023;8:368-382.
    >> Share

    March 2023
  31. MASSIRONI S, Vigano C, Palermo A, Pirola L, et al
    Inflammation and malnutrition in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Mar 15:S2468-1253(23)00011.
    >> Share

  32. BANERJEE R, Raghunathan N, Pal P
    Managing inflammatory bowel disease: what to do when the best is unaffordable?
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00062.
    >> Share

  33. BURISCH J, Zhao M, Odes S, De Cruz P, et al
    The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00003.
    >> Share

    February 2023
  34. OTTEN AT, Bourgonje AR, Visschedijk MC
    Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD.
    Lancet Gastroenterol Hepatol. 2023;8:99-100.
    >> Share

  35. FEAGAN BG, Sands BE, Sandborn WJ, Germinaro M, et al
    Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
    Lancet Gastroenterol Hepatol. 2023 Feb 1:S2468-1253(22)00427.
    >> Share

  36. VERMEIRE S
    Combination biologic therapy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 Feb 1:S2468-1253(23)00008.
    >> Share

    January 2023
  37. DREESEN E, Verstockt B
    A personalised taper-to-target strategy with adalimumab in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2023 Jan 31:S2468-1253(23)00009.
    >> Share

  38. VAN LINSCHOTEN RCA, Jansen FM, Pauwels RWM, Smits LJT, et al
    Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2023 Jan 31:S2468-1253(22)00434.
    >> Share

  39. LOUIS E, Resche-Rigon M, Laharie D, Satsangi J, et al
    Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2023 Jan 11:S2468-1253(22)00385.
    >> Share

  40. FREDERICKS E
    Treatment withdrawal in Crohn's disease: slowly becoming clearer.
    Lancet Gastroenterol Hepatol. 2023 Jan 11:S2468-1253(22)00405.
    >> Share

  41. KAMMERMEIER J, Lamb CA, Jones KDJ, Anderson CA, et al
    Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutri
    Lancet Gastroenterol Hepatol. 2023 Jan 9:S2468-1253(22)00337.
    >> Share

  42. THORLEY J
    Severine Vermeire: advancing patient-centred research in IBD.
    Lancet Gastroenterol Hepatol. 2023;8:17.
    >> Share

  43. SANDBORN WJ, Panes J, Danese S, Sharafali Z, et al
    Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2023;8:43-55.
    >> Share

    December 2022
  44. LIU Z, Le K, Zhou X, Alexander JL, et al
    Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a p
    Lancet Gastroenterol Hepatol. 2022 Dec 5:S2468-1253(22)00389.
    >> Share

  45. ALLEGRETTI JR
    Should faecal microbiota transplantation be used earlier in the treatment framework?
    Lancet Gastroenterol Hepatol. 2022;7:1062-1063.
    >> Share

    November 2022
  46. NOOR NM, Siegel C
    Partially randomised, patient preference trials for inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022;7:981-983.
    >> Share

    October 2022
  47. ATIA O, Shavit-Brunschwig Z, Mould DR, Stein R, et al
    Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Lancet Gastroenterol Hepatol. 2022 Oct 25. pii: S2468-1253(22)00307.
    >> Share

  48. QUAN J, Ma C, Panaccione R, Hracs L, et al
    Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022 Oct 25. pii: S2468-1253(22)00340.
    >> Share

    September 2022
  49. SELIM R, Wellens J, Brann S, Marlow L, et al
    Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.
    Lancet Gastroenterol Hepatol. 2022 Sep 21. pii: S2468-1253(22)00302.
    >> Share

  50. ALEXANDER JL, Liu Z, Munoz Sandoval D, Reynolds C, et al
    COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Lancet Gastroenterol Hepatol. 2022 Sep 8. pii: S2468-1253(22)00274.
    >> Share

  51. VERMEIRE S, Sands BE, Tilg H, Tulassay Z, et al
    ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
    Lancet Gastroenterol Hepatol. 2022 Sep 5. pii: S2468-1253(22)00233.
    >> Share

  52. ATREYA R, Neurath MF
    Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2022 Sep 5. pii: S2468-1253(22)00249.
    >> Share

    August 2022
  53. TIAN H, Zhang S, Qin H, Li N, et al
    Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China.
    Lancet Gastroenterol Hepatol. 2022;7:702-703.
    >> Share

    July 2022
  54. ANANTHAKRISHNAN AN, Kaplan GG, Bernstein CN, Burke KE, et al
    Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.
    Lancet Gastroenterol Hepatol. 2022;7:666-678.
    >> Share

  55. MEIMA-VAN PRAAG EM, van Rijn KL, Wasmann KATGM, Snijder HJ, et al
    Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:617-626.
    >> Share

    June 2022
  56. WATERMEYER G, Awuku Y, Fredericks E, Epstein D, et al
    Challenges in the management of inflammatory bowel disease in sub-Saharan Africa.
    Lancet Gastroenterol Hepatol. 2022 Jun 29. pii: S2468-1253(22)00048.
    >> Share

  57. WATERMEYER G, Katsidzira L, Setshedi M, Devani S, et al
    Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis.
    Lancet Gastroenterol Hepatol. 2022 Jun 29. pii: S2468-1253(22)00047.
    >> Share

  58. ROSEIRA J, Estevinho MM, Bernardo S, Sousa P, et al
    Clinical efficacy of endoscopic balloon dilation for Crohn's disease strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503.
    >> Share

  59. GENERE JR, Deepak P, Kochhar GS
    Reframing self-expandable metal stents for Crohn's strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503-504.
    >> Share

  60. GELDOF J, Iqbal N, LeBlanc JF, Anandabaskaran S, et al
    Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials.
    Lancet Gastroenterol Hepatol. 2022;7:576-584.
    >> Share

    May 2022
  61. PARIGI TL, D'Amico F, Abreu MT, Rubin DT, et al
    Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.
    Lancet Gastroenterol Hepatol. 2022;7:390-391.
    >> Share

  62. THE LANCET GASTROENTEROLOGY HE
    Opacity over live vaccines in infants exposed to infliximab.
    Lancet Gastroenterol Hepatol. 2022;7:379.
    >> Share

    April 2022
  63. WELLENS J, Brann S, Adams A, Marlow L, et al
    Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022 Apr 6. pii: S2468-1253(22)00120.
    >> Share

  64. HAIFER C, Paramsothy S, Kaakoush NO, Leong RW, et al
    Oral faecal microbiota transplantation in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2022;7:286-287.
    >> Share

  65. YUAN TY, Rajesh R, Tan M
    Oral faecal microbiota transplantation in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2022;7:286.
    >> Share

  66. UNGARO RC, Colombel JF
    Treat to target with ustekinumab for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:276-277.
    >> Share

  67. DANESE S, Vermeire S, D'Haens G, Panes J, et al
    Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Lancet Gastroenterol Hepatol. 2022;7:294-306.
    >> Share

  68. LORAS C, Andujar X, Gornals JB, Sanchiz V, et al
    Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:332-341.
    >> Share

  69. GOREN I, Rieder F
    Endoscopic interventions for stricturing Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:279-280.
    >> Share

  70. SCHULBERG JD, Wright EK, Holt BA, Hamilton AL, et al
    Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2022;7:318-331.
    >> Share

    March 2022
  71. MATSUOKA K, Watanabe M, Ohmori T, Nakajima K, et al
    AJM300 (carotegrast methyl), an oral antagonist of alpha4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2022 Mar 30. pii: S2468-1253(22)00022.
    >> Share

  72. KOTZE PG, Heuthorst L, Lightner AL, Damiao AOMC, et al
    New insights on the surgical management of ulcerative colitis in the 21st century.
    Lancet Gastroenterol Hepatol. 2022 Mar 29. pii: S2468-1253(22)00001.
    >> Share

    February 2022
  73. KUENZIG ME, Widdifield J, Bernatsky S, Kaplan GG, et al
    Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.
    Lancet Gastroenterol Hepatol. 2022 Feb 22. pii: S2468-1253(22)00054.
    >> Share

  74. ALEXANDER JL, Kennedy NA, Ibraheim H, Anandabaskaran S, et al
    COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
    Lancet Gastroenterol Hepatol. 2022 Feb 3. pii: S2468-1253(22)00005.
    >> Share

  75. PAPAMICHAEL K, Afif W, Drobne D, Dubinsky MC, et al
    Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
    Lancet Gastroenterol Hepatol. 2022;7:171-185.
    >> Share

  76. OZPOLAT HT, Baran B, Akyuz F
    Septic arthritis: a presentation of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:196.
    >> Share

    January 2022
  77. GUILLO L, Abreu M, Panaccione R, Sandborn WJ, et al
    Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
    Lancet Gastroenterol Hepatol. 2022 Jan 17. pii: S2468-1253(21)00297.
    >> Share

  78. SASSON AN
    A whole-food exclusion diet as monotherapy for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:6-7.
    >> Share

  79. SHEN B, Kochhar GS, Rubin DT, Kane SV, et al
    Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2022;7:69-95.
    >> Share

  80. YANAI H, Levine A, Hirsch A, Boneh RS, et al
    The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:49-59.
    >> Share

    December 2021
  81. HAIFER C, Paramsothy S, Kaakoush NO, Saikal A, et al
    Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00400.
    >> Share

  82. FISCHER M, Khoruts A
    Oral lyophilised microbiota for the treatment of ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00433.
    >> Share

  83. AHMED W, Lukin DJ
    A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:973-975.
    >> Share

  84. SO D, Tuck CJ
    Plant-based diets in gastrointestinal disorders: something, nothing, or everything?
    Lancet Gastroenterol Hepatol. 2021;6:992.
    >> Share

  85. THOMAS H
    UEG Week Virtual 2021.
    Lancet Gastroenterol Hepatol. 2021;6:990.
    >> Share

  86. SINGH S, Murad MH, Fumery M, Sedano R, et al
    Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021;6:1002-1014.
    >> Share

    November 2021
  87. LASA JS, Olivera PA, Danese S, Peyrin-Biroulet L, et al
    Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00377.
    >> Share

  88. MA C, Choi MY
    Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00432.
    >> Share

  89. TAKENAKA K, Fujii T, Kawamoto A, Suzuki K, et al
    Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00372.
    >> Share

  90. PEYRIN-BIROULET L, Hart A, Bossuyt P, Long M, et al
    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00298.
    >> Share

  91. DANESE S, Colombel JF, Lukas M, Gisbert JP, et al
    Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00294.
    >> Share

  92. VERMEIRE S, Lakatos PL, Ritter T, Hanauer S, et al
    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00295.
    >> Share

  93. RUBIN DT, Dotan I, DuVall A, Bouhnik Y, et al
    Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00338.
    >> Share

  94. AGRAWAL M, Verstockt B
    Etrolizumab for ulcerative colitis: beyond what meets the eye.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00369.
    >> Share

  95. MOURAD FH, Hashash JG
    Inflammatory bowel disease in Lebanon: a plea for help.
    Lancet Gastroenterol Hepatol. 2021 Nov 11. pii: S2468-1253(21)00390.
    >> Share

  96. ASWANI-OMPRAKASH T, Sharma V, Bishu S, Balasubramaniam M, et al
    Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance.
    Lancet Gastroenterol Hepatol. 2021;6:884-885.
    >> Share

    October 2021
  97. SELIM R, Wellens J, Marlow L, Satsangi JJ, et al
    SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.
    Lancet Gastroenterol Hepatol. 2021 Oct 13. pii: S2468-1253(21)00347.
    >> Share

  98. ALEXANDER JL, Selinger CP, Powell N
    Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Oct 12. pii: S2468-1253(21)00374.
    >> Share

  99. SHEN B, Kochhar GS, Kariv R, Liu X, et al
    Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2021;6:826-849.
    >> Share

  100. HANAUER S, Liedert B, Balser S, Brockstedt E, et al
    Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2021;6:816-825.
    >> Share

    September 2021
  101. SHEN B, Bortlik M, Bruining DH, Coelho-Prabhu N, et al
    Endoscopic evaluation after surgery in inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:691-692.
    >> Share

  102. SYAL G, Fleshner PR, Melmed GY
    Endoscopic evaluation after surgery in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:690-691.
    >> Share

  103. KOBAYASHI T
    Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:688.
    >> Share

  104. TAN M, Ng V, Lim CT, Leow WQ, et al
    Stringent criteria for withdrawal of biologics in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021;6:687-688.
    >> Share

    August 2021
  105. FIORINO G, Allocca M, Danese S
    Adalimumab biosimilar in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Aug 10. pii: S2468-1253(21)00266.
    >> Share

  106. GEYL S, Guillo L, Laurent V, D'Amico F, et al
    Transmural healing as a therapeutic goal in Crohn's disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2021;6:659-667.
    >> Share

    July 2021
  107. SASSON AN, Ingram RJM, Zhang Z, Taylor LM, et al
    The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Jul 13. pii: S2468-1253(21)00097.
    >> Share

  108. GARRIDO HMG, Grobusch MP, D'Haens GRAM, Goorhuis A, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:523.
    >> Share

  109. ALEXANDER JL, Kennedy NA, Lees CW, Ahmad T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:523-524.
    >> Share

  110. DIN S, Gaya DR, Arnott IDR
    COVID-19: Colorectal cancer endoscopic surveillance in IBD.
    Lancet Gastroenterol Hepatol. 2021;6:526-527.
    >> Share

    June 2021
  111. CROFT NM, Faubion WA Jr, Kugathasan S, Kierkus J, et al
    Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Jun 18. pii: S2468-1253(21)00142.
    >> Share

    May 2021
  112. ALEXANDER JL, Powell N
    SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?
    Lancet Gastroenterol Hepatol. 2021 May 25. pii: S2468-1253(21)00184.
    >> Share

  113. DANESE S, Parigi TL, Peyrin-Biroulet L, Ghosh S, et al
    Defining difficult-to-treat inflammatory bowel disease: why and how.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00141.
    >> Share

  114. ALSOUD D, Verstockt B, Fiocchi C, Vermeire S, et al
    Breaking the therapeutic ceiling in drug development in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00065.
    >> Share

  115. SEGAL JP, Kumar A, Raine T, Lamb CA, et al
    The impact of SARS-CoV-2 variants on IBD management.
    Lancet Gastroenterol Hepatol. 2021;6:343-344.
    >> Share

    April 2021
  116. UNGAR B
    Infliximab discontinuation in patients with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00103.
    >> Share

  117. KOBAYASHI T, Motoya S, Nakamura S, Yamamoto T, et al
    Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00062.
    >> Share

  118. SHEN B, Kochhar GS, Navaneethan U, Cross RK, et al
    Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group.
    Lancet Gastroenterol Hepatol. 2021 Apr 16. pii: S2468-1253(20)30394.
    >> Share

    March 2021
  119. BARBERIO B, Zamani M, Black CJ, Savarino EV, et al
    Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00014.
    >> Share

  120. KEEFER L
    What can we do to tackle anxiety and depression in patients with inflammatory bowel disease?
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00066.
    >> Share

  121. SEGAL JP, Kayal M, Kochhar G, Dubinsky MC, et al
    The ileoanal pouch: the next frontier in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:164-165.
    >> Share

  122. JENA A, Jha DK, Sharma V
    Distinguishing intestinal tuberculosis from Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:159.
    >> Share

  123. BANERJEE R, Pal P
    Distinguishing intestinal tuberculosis from Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:159-160.
    >> Share

    February 2021
  124. SEBASTIAN S, Walker GJ, Kennedy NA, Conley TE, et al
    Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00016.
    >> Share

  125. SHEN B
    Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00009.
    >> Share

  126. VERMA AM, Patel A, Subramanian S, Smith PJ, et al
    From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Lancet Gastroenterol Hepatol. 2021;6:88-89.
    >> Share

    January 2021
  127. ALEXANDER JL, Moran GW, Gaya DR, Raine T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
    Lancet Gastroenterol Hepatol. 2021 Jan 25. pii: S2468-1253(21)00024.
    >> Share

    December 2020
  128. NG SC, Mak JWY, Pal P, Banerjee R, et al
    Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1089-1100.
    >> Share

  129. BANERJEE R, Pal P, Mak JWY, Ng SC, et al
    Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1076-1088.
    >> Share

  130. STRID H
    Prevalence of IBS-type symptoms in IBD.
    Lancet Gastroenterol Hepatol. 2020;5:1029-1031.
    >> Share

    November 2020
  131. AZIZ I, Simren M
    The overlap between irritable bowel syndrome and organic gastrointestinal diseases.
    Lancet Gastroenterol Hepatol. 2020 Nov 12. pii: S2468-1253(20)30212.
    >> Share

    October 2020
  132. MA C, Panaccione R
    Harnessing localised delivery of gut-selective therapy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30292.
    >> Share

  133. ATREYA R, Peyrin-Biroulet L, Klymenko A, Augustyn M, et al
    Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30301.
    >> Share

  134. BRENNER EJ, Ungaro RC, Colombel JF, Kappelman MD, et al
    IBD in the COVID-19 era: the value of international collaboration.
    Lancet Gastroenterol Hepatol. 2020;5:887-888.
    >> Share

  135. STEVENS TW, Haasnoot ML, D'Haens GR, Buskens CJ, et al
    Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
    Lancet Gastroenterol Hepatol. 2020;5:900-907.
    >> Share

  136. FAIRBRASS KM, Costantino SJ, Gracie DJ, Ford AC, et al
    Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2020 Oct 1. pii: S2468-1253(20)30300.
    >> Share

    May 2020
  137. LOUGHMAN A, Staudacher HM
    Treating the individual with diet: is gut microbiome testing the answer?
    Lancet Gastroenterol Hepatol. 2020;5:437.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016